Novartis Ag

Novartis Pharma Gmbh

Hans Michael Buerger

Paul William Manley

Gottfried Sedelmeier

Giorgio Caravatti

Werner Breitenstein

Mark Meisenbach

Daniel Kaufmann

Stephan Abel

Beat Schmitz

Olivier Loiseleur

Margaret A Cudd

Juerg Zimmermann

Juerg Zimmerman

Uerg Zimmermann

Bertrand Sutter

The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-yl-methyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I, which may be used for example for tumour therapy.

Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

The invention relates to N-phenyl-2-pyrimidine-amine derivatives of formula I wherein the substituents are defined as indicated in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

N-phenyl-3-pyrimidine-amine derivatives

N-phenyl-2-pyrimidine-amine derivatives

The invention relates to N-phenyl-2-pyrimidine-amine derivatives of formula (I) wherein the substituents are defined as in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

Growing community of inventors

Allschwil, Switzerland

Hans Michael Buerger